glp-1-based weight-loss drugs GLP-1 weight loss leave users low on key nutrients, study finds Food companies are targeting users

Clinical trials measuring body composition found that fat mass reductions occurred without corresponding increases in lean tissue mass, confirming the absence of anabolic muscle-building effects

Novo Nordisk: CagriSema Cagrilinitide is an analogue (a drug made to mimic a molecule already present in the body) of amylin, which acts as an agonist for calcitonin receptors

Williams DL, Nagaoka A, Kitami A, Mitsuhashi T, Hayakawa Y, Kobayashi M

For those seeking a more affordable option, oral supplements, topical serums, and lifestyle changes can provide steady support for skin health without the risks of infusion therapy

The market size for the GLP-1 diabetes treatment drugs market is projected to reach USD 62,543.2 million by 2035